Studying HIV drug resistance in adults treated in Mozambique
Observes whether poorly controlled HIV develops resistance to dolutegravir and related drugs.
Key facts
- Who runs it
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Where
- Chokwé, MozambiqueSee the site
- Trial code
- Registry title
- Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 25 Oct 2024
- Planned end
- Sept 2026
- Type of study
- Observational
- Treatments tested
- Not applicable- observational study
- Record updated
- 15 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with HIV-1 who have taken first-line TLD for at least 6 months and still have a detectable amount of virus in the blood.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- HIV-1 infection with a viral load above 200 c/ml for at least 3 months of follow-up
- Earlier treatment
- Must have taken first-line TLD for at least 6 months. A first-line regimen other than TLD is not allowed.
- Biomarker or test result
- Viral load above 200 c/ml over at least 3 months of follow-up
Main reasons for not taking part
- Younger than 18 years
- First-line regimen other than TLD
- Active cancer
- Active opportunistic disease
- Unable to give informed consent
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients able to understand and sign the informed consent form
- Documented HIV-1 infection
- Under the first line TLD for at least 6 months
- At least 3 months follow-up with CV \>200c/ml
Who cannot take part
- Patients with active opportunistic diseases
- Patients \<18 years of age
- Under the first line regime other than TLD
- Patients with active neoplastic processes
- Patients unable to give informed consent
Where in Mozambique
- Hospital CarmeloChokwé, MozambiqueContact: Elsa Jordao, MDTaking people
About the trial
What the trial wants to find out
The HIV infection not fully controlled, despite being under antiretroviral treatment, could make virus resistance against the antiretroviral treatments, making hardest the well control of HIV infection. The purpose of this research study is to confirm or deny if a not fully good controlled HIV infection could develop virus resistance against antiretroviral drugs that can difficult the good control of the HIV infection.
The group in the trial
- HIV-1 infected men or women >18 years controlled in the day care center of Chokwé Hospital
Treatment: Not applicable- observational study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Selection of Resistant Mutations to Dolutegravir and Associated Drugs in PLWH Treated in Clinical Practice in Chokwé, Mozambique
- Plain-language title
- Studying HIV drug resistance in adults treated in MozambiqueGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 15 May 2025